"Overall, the seven additional serotypes in Prevnar 20 account for approximately 40% of all pneumococcal disease cases and deaths in the US," said the drugmaker. Around 10,000 American adults a ...

Pneumococcal 20-valent conjugate vaccine (diphtheria CRM197 protein); contains a total of 46.2mcg saccharides per 0.5mL; susp for IM inj; contains aluminum. After shipping, Prevnar 20 may arrive ...

All told, Capvaxive encompasses the serotypes responsible for around 84% of IPD cases in adults aged 50 and over, compared to around 52% with Prevnar 20, according to data from the Centers for ...

It protects against 15 serotypes. PCV20, also known as Prevnar 20, was licensed in 2021 for adults 18 years and older, then in 2023 was recommended for ages 6 weeks and up. It covers 20 serotypes.

MRK markets another PCV vaccine, Vaxneuvance, which is approved for 15 serotypes in older adults. Pfizer PFE is a key player ...

Previously, CDC guidelines for adult PCVs broadly targeted only those older than 65. Currently available PCVs for the recommended age group include Pfizer’s Prevnar 20 and Merck’s Capvaxive.

PFE markets Prevnar 20, which is approved for the prevention ... license and commercialize next-generation PCVs for treating IPD in pediatric and adult patient populations in December 2024.